# Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

> **NCT04166734** · PHASE1 · TERMINATED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 5 (actual)

## Conditions studied

- Advanced Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT04166734
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-12
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study terminated due to slow recruitment and insufficient further funding.
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166734, "Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04166734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*